Mitomycin Substipharm (Mitomycin)

Mitomycin functions as a DNA cross‑linking alkylating agent. After activation inside cancer cells, it creates free radicals that bind DNA strands together, blocking replication and transcription. This DNA damage triggers programmed cell death, preferentially affecting rapidly dividing tumour cells while sparing most normal tissues.

The specific dose of Mitomycin Substipharm is determined by the treating oncologist based on the patient’s diagnosis, disease stage, body surface area and overall health. Dosing regimens vary between intravesical and intravenous administration and are individualized for each clinical situation.

Mitomycin is classified as contraindicated in pregnancy because it can cause fetal harm. Women of child‑bearing potential should use effective contraception during treatment and for a period afterward. Breastfeeding should be discontinued while receiving Mitomycin, as the drug may be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Mitomycin Substipharm. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Compared with many conventional alkylating agents, Mitomycin has a unique mechanism of DNA cross‑linking and generates free radicals, giving it activity against tumours resistant to other drugs. However, its toxicity profile, especially bladder and marrow effects, may be more pronounced, requiring careful monitoring and supportive care.

Mitomycin Substipharm should be stored refrigerated at 2‑8 °C, protected from light, and kept in its original container to maintain stability. It must not be frozen or shaken. During handling, use aseptic technique and wear appropriate protective equipment to avoid accidental exposure.

Mitomycin is administered either intravenously as an infusion in a clinical setting or intravesically directly into the bladder for non‑muscle‑invasive bladder cancer. The route, infusion rate and schedule are determined by the prescribing oncologist and are performed by qualified healthcare professionals.

The most serious adverse events include severe myelosuppression leading to infection or bleeding, hemorrhagic cystitis with potential bladder damage, pulmonary toxicity such as interstitial pneumonitis, and acute renal impairment. Prompt recognition and supportive management are essential to mitigate these risks.

Mitomycin is contraindicated in patients with known hypersensitivity to the drug, in pregnant women, and in individuals with severe pre‑existing bone‑marrow suppression, uncontrolled infections, or significant renal impairment. It should also be avoided in patients receiving other highly nephrotoxic or myelosuppressive therapies unless closely monitored.